Kaempferol Clinical Trials

Size	Price	Qty
50mg	USD 147
200mg	USD 247

Clinical Trials

Several clinical trials are evaluating kaempferol across diverse therapeutic applications, including healthy dietary biomarkers, female sexual dysfunction, mitochondrial health and pharmacokinetics, skin biophysical properties, and peri-implant bone healing. Sponsored by academic institutions, these early-stage studies—designated as Phase 1 or Not Applicable—reflect a mix of completed protocols and active recruitment.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07322406	RECRUITING	No Disease; Mitochondria Health; Longevity; Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult; Healthy Volunteers	University of Pittsburgh	2025-12-09
NCT07458334	RECRUITING	Skin Biophysical Properties	Kaohsiung Medical University Chung-Ho Memorial Hospital	2026-02-09
NCT07156799	COMPLETED	Peri-implant Bone Healing and Osseointegration	Al-Azhar University	2023-06-05
NCT06060691	COMPLETED	Female Sexual Dysfunction	Deraya University	2023-09-20	PHASE1
NCT05073523	Completed	Healthy	Chalmers University of Technology	2021-09-27	Not Applicable

(data from https://clinicaltrials.gov, updated on 2026-03-23)

Check the Kaempferol product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Kaempferol functions as an inverse agonist of estrogen-related receptors ERRα and ERRγ while inhibiting topoisomerase I-catalyzed DNA religation and fatty acid synthase activity, thereby disrupting receptor-mediated transcription and lipogenic signaling pathways. This target modulation downregulates cellular bioenergetics and cellular proliferation, providing a mechanistically relevant rationale for its clinical exploration in mitochondrial health, skin biophysical maintenance, and peri-implant tissue healing.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).